keyword
MENU ▼
Read by QxMD icon Read
search

Polypill

keyword
https://www.readbyqxmd.com/read/29325730/use-of-cardiovascular-polypills-for-the-secondary-prevention-of-cerebrovascular-disease
#1
J Masjuan, J Gállego, J M Aguilera, J F Arenillas, M Castellanos, F Díaz, J C Portilla, F Purroy
INTRODUCTION: There is little control of cardiovascular (CV) risk factors in secondary prevention after an ischaemic stroke, in part due to a lack of adherence to treatment. The CV polypill may contribute to proper treatment adherence, which is necessary for CV disease prevention. This study aimed to establish how and in what cases the CV polypill should be administered. METHODS: A group of 8 neurologists drafted consensus recommendations using structured brainstorming and based on their experience and a literature review...
January 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29316126/fixed-dose-combination-therapy-to-reduce-the-growing-burden-of-cardiovascular-disease-in-low-and-middle-income-countries-feasibility-and-challenges
#2
REVIEW
Jobert Richie Nansseu, Aurel T Tankeu, Joseph Kamtchum-Tatuene, Jean Jacques Noubiap
Cardiovascular disease (CVD) has become a major concern in low- and middle-income countries, which bear about 80% of the cardiovascular mortality worldwide. Curbing the burden of CVD implies the management and control of many cardiovascular risk factors that act synergistically to increase cardiovascular mortality. Such actions may require expensive polymedications in a context of limited resources. Therefore, alternative solutions for CVD prevention in low- and middle-income countries are urgently needed. In this context, the concept of a fixed-dose combination therapy, a polypill composed of drugs known to effectively treat or prevent CVD, has been proposed as a scalable strategy to overcome nonadherence to polymedications and reduce costs...
January 6, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29251761/single-pill-combinations-spcs-and-treatment-of-arterial-hypertension-in-poland-expert-consensus-statement-of-the-polish-society-of-hypertension-and-polish-cardiac-society-working-group-on-cardiovascular-pharmacotherapy
#3
Andrzej Tykarski, Krystyna Widecka, Krzysztof Narkiewicz, Beata Wożakowska-Kapłon, Zbigniew Gaciong, Stefan Grajek, Tomasz Grodzicki, Andrzej Januszewicz, Jacek Wolf, Aleksander Prejbisz, Katarzyna Kostka-Jeziorny, Krzysztof J Filipiak
The reasons for the publication of current expert consensus statement after 4 years from the previous one are: the growing number of evidence on the benefits of the use of single-pill combinations (SPCs) in hypertension (also with concomitant dyslipidaemia), the extension of indications for their use in the hypertension management algorithm and the emergence in recent years after the publication of Polish Society of Hypertension experts' position statement in 2013 of new types of SPCs available to doctors in Poland, including triple-drug combinations of antihypertensives and the so-called "hybrids" SPCs containing not only antihypertensive drugs but also statins...
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29224179/antidiabetic-polypill-improves-central-pathology-and-cognitive-impairment-in-a-mixed-model-of-alzheimer-s-disease-and-type-2-diabetes
#4
Carmen Infante-Garcia, Juan Jose Ramos-Rodriguez, Carmen Hierro-Bujalance, Esperanza Ortegon, Eleanor Pickett, Rosemary Jackson, Fernando Hernandez-Pacho, Tara Spires-Jones, Monica Garcia-Alloza
Type 2 diabetes (T2D) is an important risk factor to suffer dementia, being Alzheimer's disease (AD) as the most common form. Both AD and T2D are closely related to aging and with a growing elderly population it might be of relevance to explore new therapeutic approaches that may slow or prevent central complications associated with metabolic disorders. Therefore, we propose the use of the antidiabetic polypill (PP), a pharmacological cocktail, commonly used by T2D patients that include metformin, aspirin, simvastatin, and an angiotensin-converting enzyme inhibitor...
December 9, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/29180263/polypill-hypertension-and-medication-adherence-the-solution-strategy
#5
D Cimmaruta, N Lombardi, C Borghi, G Rosano, F Rossi, A Mugelli
INTRODUCTION: Hypertension is an important global health challenge and a leading preventable risk factor for premature death and disability worldwide. In current cardiology practice, the main obstacles in the management of patients affected by hypertension are comorbidities and poor adherence to pharmacological treatments. The World Health Organization has recently highlighted increased adherence as a key development need for reducing cardiovascular disease. METHODS: Principal observational and clinical trial data regarding adherence, reductions in cardiovascular risk and safety of the polypill approach are summarized and reviewed...
February 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29127755/-metabolic-syndrome-and-the-role-of-the-polypill-in-the-prevention-of-its-complications
#6
Hana Rosolová
The first mention concerning occurrence of cardiometabolic risk factors together appeared 100 years ago. Metabolic syndrome brings 5times higher risk for type 2 diabetes development and 2-3tímes higher cardiovascular (CV) risk in comparison to the subjects without that syndrome. Healthy life habits and rational pharmacotherapy of hypertension, dyslipidemia and hyperglycemia represent an effective way for high cardiometabolic risk reduction. The problem are patient´s low adherence and persistence to the recommendation and pharmacotherapy...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29095234/in-polypills-as-in-any-recipe-it-s-ingredients-that-matter
#7
Louis Hofstetter, Stefano F Rimoldi, Franz H Messerli
No abstract text is available yet for this article.
December 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28986058/impact-of-switching-to-polypill-based-therapy-by-baseline-potency-of-medication-post-hoc-analysis-of-the-space-collaboration-dataset
#8
Ruth Webster, Chris Bullen, Anushka Patel, Vanessa Selak, Sandrine Stepien, Simon Thom, Anthony Rodgers
BACKGROUND: Fixed dose combinations of cardiovascular therapy ('polypills') have now been launched in several dozen countries. There is considerable clinical interest in the effects of switching to polypill-based care from typical current treatment regimens, especially if polypills contain components at sub-maximal dosage. METHODS: The SPACE Collaboration includes three trials of polypill based care vs usual care in patients with established CVD or at high calculated risk...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28882196/simultaneous-determination-of-acetylsalicylic-acid-hydrochlorothiazide-enalapril-and-atorvastatin-in-a-polypill-based-quaternary-mixture-by-tlc
#9
Anna Maślanka, Mariusz Stolarczyk, Anna Apola, Anna Kwiecień, Urszula Hubicka, Włodzimierz Opoka
A new chromatographic-densitometric method has been developed for the qualitative and quantitative determination of the active ingredients in a simulated mixture corresponding to the PolyIran polypill, composed of acetylsalicylic acid, hydrochlorothiazide (HCT), enalapril (ENA), and atorvastatin (ATR), whose efficacy in the treatment and prevention of cardiovascular disease has been documented in clinical trials. Chromatographic separation was performed using TLC silica gel 60 plates with fluorescent indicator F254 as the stationary phase and a mixture of n-hexane-ethyl acetate-methanol-water-acetic acid (8...
September 7, 2017: Journal of AOAC International
https://www.readbyqxmd.com/read/28873416/cost-effectiveness-analysis-of-use-of-a-polypill-versus-usual-care-or-best-practice-for-primary-prevention-in-people-at-high-risk-of-cardiovascular-disease
#10
Sue Jowett, Pelham Barton, Andrea Roalfe, Kate Fletcher, F D Richard Hobbs, Richard J McManus, Jonathan Mant
BACKGROUND: Clinical trials suggest that use of fixed-dose combination therapy ('polypills') can improve adherence to medication and control of risk factors of people at high risk of cardiovascular disease (CVD) compared to usual care, but cost-effectiveness is unknown. OBJECTIVE: To determine whether a polypill is cost-effective compared to usual care and optimal guideline-recommended treatment for primary prevention in people already on statins and/or blood pressure lowering therapy...
2017: PloS One
https://www.readbyqxmd.com/read/28652091/investigating-therapeutic-usage-of-combined-ticagrelor-and-aspirin-through-solid-state-and-analytical-studies
#11
Hassane Sadou Yayé, Ivo B Rietveld, Maria Barrio, Philippe-Henri Secrétan, Antoine Faucheron, Maher Karoui, Patrick Tilleul, Najet Yagoubi, Bernard Do
The mainstay treatment for patients with acute coronary syndrome is an oral route dual antiplatelet therapy with a P2Y12-receptor antagonist and Aspirin (ASA). To improve patient adherence to such treatments, combination therapies (polypill) are envisioned. Physicochemical solid-state studies have been carried out to develop a preformulation strategy of ASA with the P2Y12-receptor antagonist Ticagrelor (TIC). The investigations were carried out using differential scanning calorimetry, liquid chromatography-high resolution-multistage mass spectrometry (LC-HR-MS(n)) and as complementary techniques Fourier transform infrared measurements and thermogravimetric analysis...
June 23, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28645284/healthcare-expenditure-on-indigenous-and-non-indigenous-australians-at-high-risk-of-cardiovascular-disease
#12
Blake Angell, Tracey-Lea Laba, Tom Lung, Alex Brown, Sandra Eades, Tim Usherwood, David Peiris, Laurent Billot, Graham Hillis, Ruth Webster, Andrew Tonkin, Christopher Reid, Barbara Molanus, Natasha Rafter, Alan Cass, Anushka Patel, Stephen Jan
BACKGROUND: In spite of bearing a heavier burden of death, disease and disability, there is mixed evidence as to whether Indigenous Australians utilise more or less healthcare services than other Australians given their elevated risk level. This study analyses the Medicare expenditure and its predictors in a cohort of Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. METHODS: The healthcare expenditure of participants of the Kanyini Guidelines Adherence with the Polypill (GAP) pragmatic randomised controlled trial was modelled using linear regression methods...
June 23, 2017: International Journal for Equity in Health
https://www.readbyqxmd.com/read/28618914/role-of-the-polypill-for-secondary-prevention-in-ischaemic-heart-disease
#13
José M Castellano, Valentín Fuster, Catriona Jennings, Eva Prescott, Héctor Bueno
In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition...
June 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28576674/public-park-spaces-as-a-platform-to-promote-healthy-living-introducing-a-healthpark-concept
#14
REVIEW
Ross Arena, Samantha Bond, Robert O'Neill, Deepika R Laddu, Andrew P Hills, Carl J Lavie, Amy McNeil
The concept of Healthy Living (HL) as a primary medical intervention continues to gain traction, and rightfully so. Being physically active, consuming a nutritious diet, not smoking and maintaining an appropriate body weight constitute the HL polypill, the foundation of HL medicine (HLM). Daily use of the HL polypill, working toward optimal dosages, portends profound health benefits, substantially reducing the risk of chronic disease [i.e., cardiovascular disease (CVD), pulmonary disease, metabolic syndromes, certain cancers, etc...
June 2017: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/28566321/effect-of-intensive-glucose-control-on-microvascular-events-in-people-with-type-2-diabetes
#15
(no author information available yet)
Effect of intensive glucose control on microvascular events in people with type 2 diabetes ● Febrile seizures in children: benefits and risks of prophylactic drug management More on gastric acid suppression and C difficile risk ● What next for the cardiovascular polypill? ● EMA recommends suspension of some generic drugs ● Phototherapy for vitiligo ● WHO targets medication-related errors.
May 31, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28566319/what-next-for-the-cardiovascular-polypill
#16
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28552061/polypharmacy-in-cardiovascular-medicine-problems-and-promises
#17
Mehran Abolbashari, Tracy E Macaulay, Thomas F Whayne, Debabrata Mukherjee, Sibu Saha
Polypharmacy is now a frequent aspect and reality of current medicine practice, driven by managing multiple comorbidities, especially in older adults. However and unfortunately, polypharmacy can expose patients to adverse drug reactions, and drug-drug or drug-disease interactions. On the other hand, clinicians are often hesitant to add new drugs to complex regimens even when recommended by evidence-based medicine and guidelines. In addition, there is frequently a failure to assess which medications might not be beneficial and may therefore be stopped...
May 28, 2017: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28467941/metabolic-surgery-in-a-pill
#18
Alexander D Miras, Carel W le Roux
Bariatric surgery has evolved from a very effective treatment of weight to a treatment of "metabolism" and end-organ damage. Even though surgery was designed with the aim of causing mechanical restriction and calorie malabsorption, mechanistic work in humans and rodents over the last 10 years or so has informed us that this could not be further from the truth. Dietary, pharmacological, and medical device interventions for weight loss and metabolic control have also evolved rapidly only very recently. In this Crosstalk we discuss how close we are to harnessing the clinical efficacy of surgery through a metabolic "polypill...
May 2, 2017: Cell Metabolism
https://www.readbyqxmd.com/read/28448291/the-polypill-in-cardiovascular-prevention-evidence-limitations-and-perspective-position-paper-of-the-european-society-of-hypertension
#19
Antonio Coca, Enrico Agabiti-Rosei, Renata Cifkova, Athanasios J Manolis, Josep Redón, Giuseppe Mancia
: Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective implementation of these treatments is rare, and thus their contribution to cardiovascular prevention is much less than it could be, based on research data. This article reviews the pros and cons of cardiovascular prevention by the polypill approach. It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors...
August 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28436727/impact-of-switching-from-different-treatment-regimens-to-a-fixed-dose-combination-pill-polypill-in-patients-with-cardiovascular-disease-or-similarly-high-risk
#20
Melvin Lafeber, Wilko Spiering, Frank Lj Visseren, Diederick E Grobbee, Michiel L Bots, Alice Stanton, Anushka Patel, Dorairaj Prabhakaran, Ruth Webster, Simon Thom, Anthony Rodgers
Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the widespread lack of access and adherence to proven medicines. Initiation of polypill-based care typically entails switching from current separately taken medications. Given the heterogeneity in usual care, there is interest in the impact of polypill treatment across different patterns of prior medication regimen. Methods A total of 2004 participants with established cardiovascular disease or estimated 5-year cardiovascular risk of over 15% were randomised to polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12...
January 1, 2017: European Journal of Preventive Cardiology
keyword
keyword
11650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"